Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14989523 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1340804 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9503018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| Octane SCHEMBL16440085 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345503 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL440982 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1066766 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1517931 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL571427 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL136430 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059896-A | Ionizable lipid gene vector and organ selective regulation method | 南开大学 | 2026-05-19 | — | — | CN | claimed |
| CN-112996519-B | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2025-02-28 | — | — | CN | claimed |
| WO-2025043179-A1 | NANOPARTICLE FORMULATIONS FOR CREATION OF IN SITU CAR T CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-27 | — | — | WO | claimed |
| US-20250064752-A1 | COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-27 | — | — | US | claimed |
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-28 | — | — | US | claimed |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| US-20240374511-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| CN-118697901-A | Inhalation type IL-10 mRNA nanometer preparation and preparation method and application thereof | 良渚实验室 | 2024-09-27 | — | — | CN | claimed |
| US-20240299310-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | RECODE THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| US-20240277850-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | RECODE THERAPEUTICS, INC. | 2024-08-22 | — | — | US | claimed |
| WO-2021159040-A2 | SARS-COV-2 MRNA DOMAIN VACCINES | MODERNATX, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021155243-A1 | RESPIRATORY VIRUS IMMUNIZING COMPOSITIONS | MODERNATX, INC. (US) | 2021-08-05 | — | — | WO | claimed |
| WO-2021154763-A1 | CORONAVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2021-08-05 | — | — | WO | claimed |
| US-20210228707-A1 | CORONAVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2021-07-29 | — | — | US | claimed |
| CN-112996519-A | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2021-06-18 | — | — | CN | claimed |
| CN-112930198-A | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2021-06-08 | — | — | CN | claimed |
| CN-112543639-A | Lipid nanoparticle compositions for delivery of MRNA and long nucleic acids | 德克萨斯大学系统董事会 | 2021-03-23 | — | — | CN | claimed |
| WO-2021050864-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2021-03-18 | — | — | WO | claimed |
| EP-3229842-A1 | LIPOCATIONIC POLYMERS AND USES THEREOF | The Board of Regents of The University of Texas System (US) | 2017-10-18 | — | — | EP | claimed |
| WO-2016094342-A1 | LIPOCATIONIC POLYMERS AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-06-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | FAAH 1818/4885CES1 297/4885CES2 1389/4885 |
| US-20240299310-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | DNAH12, DYNC1I2, DYNLL1 | FAAH 3910/4885CES1 3364/4885CES2 4290/4885 |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | FAAH 1818/4885CES1 297/4885CES2 1389/4885 |
| US-20240277850-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | DNAH12, DYNC1I2, DYNLL1 | FAAH 3910/4885CES1 3364/4885CES2 4290/4885 |
| US-20250064752-A1 | COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH | NSUN3, TRMT1L, TRMT1 | FAAH 4564/4885CES1 2344/4885CES2 1615/4885 |
| US-20240374511-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | FAAH 1818/4885CES1 297/4885CES2 1389/4885 |
| US-20210228707-A1 | CORONAVIRUS RNA VACCINES | RNGTT, SARS1, RBM3 | FAAH 2013/4885CES1 1408/4885CES2 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.